Engineering of long-acting human growth hormone-Fc fusion proteins: Effects of valency, fusion position, and linker design on pharmacokinetics and efficacy.
Fc fusion proteins, formed by fusing an active protein to the Fc region of immunoglobulin G, are a validated strategy for extending the half-life of therapeutic proteins. Human growth hormone (hGH) Fc fusion proteins exhibit longer circulation half-lives than hGH, reducing injection frequency and im...
Saved in:
| Main Authors: | Taekyeol Lee, Dongsop Lee, Eunee Jung, Mikyung Son, Kyohwan Koo, Jaehoon Choi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0323791 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of antibody-scTRAIL Fc fusion proteins with varying valency for EGFR and TRAIL receptors
by: Dennis Michler, et al.
Published: (2025-05-01) -
Advanced human FcRn knock-in mice for pharmacokinetic profiling of therapeutic antibodies
by: SuBin Lee, et al.
Published: (2025-07-01) -
Purification of a Fc-Fusion Protein with [Bathophenathroline:metal] Complexes
by: Thisara Jayawickrama Withanage, et al.
Published: (2025-01-01) -
Dose Optimization of rhIL‐7‐hyFc for Patients With Lymphopenia Using a Neonatal Fc Receptor‐Mediated Recycling‐Based and Target‐Mediated Drug Disposition Pharmacokinetic Model
by: Hye Seon Jeon, et al.
Published: (2025-05-01) -
Applying Fc-fusion proteins to tolerize perinatally and block inhibitor formation
by: David W. Scott
Published: (2025-07-01)